Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis

Z Fu; MM Brooks; S Irvin; S Jordan; KKH Aben; H Anton-Culver; EV Bandera; MW Beckmann; A Berchuck; A Brooks-Wilson; J Chang-Claude; LS Cook; DW Cramer; KL Cushing-Haugen; JA Doherty; AB Ekici; PA Fasching; RT Fortner; SA Gayther; A Gentry-Maharaj; GG Giles; EL Goode; MT Goodman; HR Harris; A Hein; R Kaaks; LA Kiemeney; M Köbel; J Kotsopoulos; ND Le; AW Lee; K Matsuo; V Mcguire; JR Mclaughlin; U Menon; RL Milne; KB Moysich; CL Pearce; MC Pike; B Qin; SJ Ramus; MJ Riggan; JH Rothstein; JM Schildkraut; W Sieh; R Sutphen; KL Terry; PJ Thompson; L Titus; AM Van Altena; E White; AS Whittemore; AH Wu; W Zheng; A Ziogas; SE Taylor; L Tang; T Songer; N Wentzensen; PM Webb; HA Risch; F Modugno

Journal article

Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis

Z Fu, MM Brooks, S Irvin, S Jordan, KKH Aben, H Anton-Culver, EV Bandera, MW Beckmann, A Berchuck, A Brooks-Wilson, J Chang-Claude, LS Cook, DW Cramer, KL Cushing-Haugen, JA Doherty, AB Ekici, PA Fasching, RT Fortner, SA Gayther, A Gentry-Maharaj Show all

Journal of the National Cancer Institute | Published : 2023

DOI: 10.1093/jnci/djad011

Abstract

Background: The role of ovulation in epithelial ovarian cancer (EOC) is supported by the consistent protective effects of parity and oral contraceptive use. Whether these factors protect through anovulation alone remains unclear. We explored the association between lifetime ovulatory years (LOY) and EOC. Methods: LOY was calculated using 12 algorithms. Odds ratios (ORs) and 95% confidence intervals (CIs) estimated the association between LOY or LOY components and EOC among 26 204 control participants and 21 267 case patients from 25 studies. To assess whether LOY components act through ovulation suppression alone, we compared beta coefficients obtained from regression models with expected es..

View full abstract

University of Melbourne Researchers

Graham Giles Author

Roger Milne Author

Related Projects (3)

Molecular Epidemiology of Ovarian Cancer: The Australian Ovarian Cancer Study National Clinical Follow-Up Core

Ovarian cancer is the seventh most common cancer in Australian women and fifth most common cause of cancer death, with approximately 1200 ne..

AUSTRALIAN OVARIAN CANCER STUDY (AOCS): A MULTIDISCIPLINARY OVARIAN CANCER RESOURCE FOR THE GENOMICS ERA

Ovarian cancer is relatively uncommon and is histologically very diverse, making it difficult to analyse ovarian cancer at a molecular level..

Molecular Epidemiology of Ovarian Research Institute

PUBLIC ABSTRACT A major obstacle to preventive strategies for ovarian cancer is the lack of recognized modifiable risk factors. Age, a pos..

Grants

Awarded by National Science Foundation

Funding Acknowledgements

R01-CA87538The Ovarian Cancer Association Consortium is funded by generous contributions from its research investigators and through anonymous donations. The Ovarian Cancer Association Consortium was funded by a grant from the Ovarian Cancer Research Fund.Funding for individual studies:AUS: The Australian Ovarian Cancer Study was supported by the U.S. Army Medical Research and Materiel Command(DAMD17-01-1-0729), National Health & Medical Research Council of Australia (199600, 400413 and 400281), Cancer Councils of New South Wales, Victoria, Queensland, South Australia and Tasmania and Cancer Foundation of Western Australia (Multi-State Applications 191, 211 and 182). The Australian Ovarian Cancer Study gratefully acknowledges additional support from Ovarian Cancer Australia and the Peter MacCallum Foundation; BAV: Funds of the University of Erlangen-Nuremberg; CON: United States National Institutes of Health (R01-CA063678, R01-CA074850; R01-CA080742); DOV:United States National Institutes of Health R01-CA112523 and R01-CA87538; GER: German Federal Ministry of Education and Research, Programme of Clinical Biomedical Research (01 GB9401) and the German Cancer Research Center (DKFZ); HAW: United States National Institutes of Health (R01-CA58598, N01-CN-55424 and N01-PC-67001); HOP: University of Pittsburgh School of Medicine Dean's Faculty Advancement Award (F.Modugno), Department of Defense (DAMD17-02-1-0669,OC20085) and United States National Cancer Institute (R21-CA267050, K07-CA080668, R01-CA95023, MO1-RR000056). Funding was also provided by the United States National Science Foundation (DGE-2217399-Modugno). The views expressed are those of the authors and do not necessarily reflect the views of the National Science Foundation; JPN: Grant-in-Aid for the Third Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare; MAY: United States National Institutes of Health (R01-CA122443, P30-CA15083, P50-CA136393); Mayo Foundation; Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen Foundation; MCC: Cohort recruitment was funded by VicHealth and Cancer Council Victoria.Additional support from the Australian National Health and Medical Research Council grants 209057, 396414, and 1074383 and infrastructure support provided by Cancer Council Victoria; NCO: United States National Institutes of Health (R01-CA76016) and the Department of Defense (DAMD17-02-1-0666);NEC: United States National Institutes of Health R01-CA54419and P50-CA105009 and Department of Defense W81XWH-10-1-02802; NJO: United States National Cancer Institute (NIH-K07CA095666, R01-CA83918, NIH-K22-CA138563, and P30-CA072720)and the Cancer Institute of New Jersey; NTH: Radboud University Medical Centre; OVA: This work was supported by Canadian Institutes of Health Research grant (MOP-86727) and by United States National Institute of Health R01CA160669-01A1; POL: Intramural Research Program of the National Cancer Institute; SON: National Health Research and Development Program, Health Canada, grant 6613-1415-53; STA: United States National Institutes of Health grants U01 CA71966 and U01 CA69417; SWH: United States National Institutes of Health grant R37-CA070867and UM1-CA182910; TBO: United States National Institutes of Health (R01-CA106414-A2), American Cancer Society (CRTG-00-196-01-CCE), Department of Defense (DAMD17-98-1-8659), Celma Mastry Ovarian Cancer Foundation; TOR: United States National Institutes of Health grants R01 CA063678 and R01 CA063682; UCI: United States National Institutes of Health R01-CA058860 and the Lon V Smith Foundation grant LVS-39420; UKO: The UKOPS study was funded by The Eve Appeal (The Oak Foundation) with contribution to author's salary through Medical Research Council core funding MC_UU_00004/01 and the National Institute for Health Research University College London Hospitals Biomedical Research Centre. UM and AGM are supported by salary contributions through Medical Research Council core funding (MC_UU_00004/01); USC: United States National Institutes of Health P01CA17054, P30CA14089, R01CA61132, N01PC67010, R03CA113148, R03CA115195, N01CN025403, and California Cancer Research Program (00-01389 V-20170, 2II0200); VTL: United States National Institutes of Health K05-CA154337.